Legal Representation
Attorney
Thomas Ewing
USPTO Deadlines
Next Deadline
2151 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20251209)
Due Date
December 09, 2031
Grace Period Ends
June 09, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 12, 2025 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED | Loading... |
| Dec 9, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Dec 9, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 21, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 21, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 15, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 20, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 19, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 19, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 19, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 12, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 27, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 27, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 24, 2025 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 23, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 22, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 4, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 4, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 3, 2025 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 042
Medical research; biological research, clinical research in the fields of immunology, autoimmunity, diagnostics and treatment of inflammation and neurodegenerative diseases, and medical research; biological research services; pharmaceutical research services; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; advisory services relating to scientific research; pharmaceutical research and development services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; medical research laboratory services; laboratory research services relating to pharmaceuticals
Additional Information
Design Mark
The mark consists of the literal element "REDOXIS" in lowercase letters. To the left of "REDOXIS" is a red circular icon containing a white abstract figure resembling a person with raised arms. The "X" in "REDOXIS" is also represented in red whilst the remaining letters are in black.
Color Claim
The color(s) red, black, and white is/are claimed as a feature of the mark.
Classification
International Classes
042